Speaker(s): 

Rates of naloxone co-prescribing among Geisinger patients on chronic opioids.
Dr, Tommy Pham, Fellow, Geisinger, has nothing to disclose.
 
Review of using buprenorphine for the treatment of alcohol use disorder.
Dr. James Simons, Geisinger, has nothing to disclose.

Moderator(s): 

Dr. Craig Riccelli, MD, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to:

Dr. Tommy Pham

  • describe opioid crisis.
  • measure the prevalence of naloxone co-prescription rates with chronic opioids in Geisinger Health System.
  • determine if there are potential changes that can be made to decrease opioid overdose rates.

Dr. James Simons

  • assess the efficacy of buprenorphine-naloxone in reducing alcohol cravings and consumption.
  • examine the outcomes of two case studies where buprenorphine-naloxone was utilized for AUD treatment.
  • discuss the potential role of buprenorphine-naloxone as an alternative therapy in challenging cases of AUD with co-occurring opioid use disorder (OUD) and complex medical conditions.
  • discuss the FDA approved medications for OUD & AUD

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Jessica Sevecke-Hanrahan,PhD, Jessie Goldhirsh, MD, Dominick Agosti, LCSW, Priscilla Riley, LPC and Lauryn Eister, MSN, CRNP, PMHNP-BC have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant. 

Commerical Support for this Session

None.

Session date: 
05/30/2024 - 11:00am to 12:00pm EDT
Location: 
Virtual Meeting
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Approved for APA Credit
  • 1.00 ASWB
  • 1.00 Participation Credit
  • 1.00 NBCC

Please login or register to take this course.